Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALIANT: Verekitug (UPB-101) Dose-ranging in Severe Asthma
jRCT2031240070Phase 2Active, not recruiting
- Sponsor
- Upstream Bio
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of vereckitug in severe asthma and asthma (4 arms), sponsored by Upstream Bio. Primary endpoint: Annualized asthma exacerbation rate over 60 weeks. Started Jun 2024; status: active, not recruiting.
02
Drugs
vereckitug
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on jRCT2031240070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240070.